Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Int J Mol Sci. 2020 Jul 9;21(14):4860. doi: 10.3390/ijms21144860.
Cachexia is a devastating pathology induced by several kinds of diseases, including cancer. The hallmark of cancer cachexia is an extended weight loss mainly due to skeletal muscle wasting and fat storage depletion from adipose tissue. The latter exerts key functions for the health of the whole organism, also through the secretion of several adipokines. These hormones induce a plethora of effects in target tissues, ranging from metabolic to differentiating ones. Conversely, the decrease of the circulating level of several adipokines positively correlates with insulin resistance, metabolic syndrome, diabetes, and cardiovascular disease. A lot of findings suggest that cancer cachexia is associated with changed secretion of adipokines by adipose tissue. In agreement, cachectic patients show often altered circulating levels of adipokines. This review reported the findings of adipokines (leptin, adiponectin, resistin, apelin, and visfatin) in cancer cachexia, highlighting that to study in-depth the involvement of these hormones in this pathology could lead to the development of new therapeutic strategies.
恶病质是由多种疾病引起的破坏性病理状态,包括癌症。癌症恶病质的标志是体重持续下降,主要是由于骨骼肌消耗和脂肪组织中脂肪储存的消耗。后者通过分泌几种脂肪因子为整个机体的健康发挥关键作用。这些激素在靶组织中引发多种作用,从代谢到分化。相反,几种脂肪因子的循环水平下降与胰岛素抵抗、代谢综合征、糖尿病和心血管疾病呈正相关。大量研究结果表明,癌症恶病质与脂肪组织分泌的脂肪因子发生改变有关。因此,恶病质患者通常表现出循环脂肪因子水平的改变。本综述报告了脂肪因子(瘦素、脂联素、抵抗素、apelin 和 visfatin)在癌症恶病质中的发现,强调深入研究这些激素在这种病理状态中的作用可能会导致新的治疗策略的发展。